Profile data is unavailable for this security.
About the company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
- Revenue in USD (TTM)0.00
- Net income in USD-14.56m
- Incorporated2008
- Employees5.00
- LocationTenax Therapeutics Inc101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL 27517United StatesUSA
- Phone+1 (919) 855-2100
- Fax+1 (302) 655-5049
- Websitehttp://www.tenaxthera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cingulate Inc | 0.00 | -16.35m | 14.94m | 13.00 | -- | 1.18 | -- | -- | -70.83 | -70.83 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -168.10 | -- | -268.55 | -- | -- | -- | -- | -- | -- | -141.37 | 0.0007 | -- | -- | -- | -33.14 | -- | -- | -- |
| IN8BIO, Inc. | 0.00 | -31.88m | 14.97m | 31.00 | -- | 1.74 | -- | -- | -0.7581 | -0.7581 | 0.00 | 0.1836 | 0.00 | -- | -- | 0.00 | -151.16 | -74.18 | -188.31 | -84.42 | -- | -- | -- | -- | -- | -- | 0.1233 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Minerva Neurosciences Inc | 0.00 | -3.31m | 15.46m | 9.00 | -- | -- | -- | -- | -0.4357 | -0.4357 | 0.00 | -3.10 | 0.00 | -- | -- | 0.00 | -6.25 | -49.89 | -6.75 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -11.21m | 15.74m | 22.00 | -- | 4.07 | -- | -- | -0.7963 | -0.7963 | 0.00 | 0.2287 | 0.00 | -- | -- | 0.00 | -158.98 | -53.28 | -199.48 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Aprea Therapeutics Inc | 1.31m | -13.51m | 15.89m | 7.00 | -- | 0.7238 | -- | 12.12 | -2.81 | -2.81 | 0.2646 | 4.28 | 0.0498 | -- | -- | 187,262.90 | -51.30 | -68.66 | -60.22 | -77.19 | -- | -- | -1,030.42 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Synlogic Inc | 2.78m | -37.18m | 16.43m | 6.00 | -- | 1.25 | -- | 5.92 | -4.09 | -4.09 | 0.258 | 1.12 | 0.0638 | -- | -- | 462,833.30 | -85.46 | -40.57 | -105.90 | -43.82 | -- | -- | -1,338.82 | -3,245.93 | -- | -- | 0.00 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
| Tenax Therapeutics Inc | 0.00 | -14.56m | 16.53m | 5.00 | -- | 0.17 | -- | -- | -15.92 | -15.92 | 0.00 | 28.52 | 0.00 | -- | -- | 0.00 | -26.08 | -199.16 | -26.84 | -285.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.21 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 14.69k | -13.32m | 17.11m | 12.00 | -- | 0.1607 | -- | 1,164.92 | -80.82 | -80.82 | 0.0797 | 34.41 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 0.00 | -6.59m | 17.51m | 4.00 | -- | 4.13 | -- | -- | -0.8556 | -0.8556 | 0.00 | 0.487 | 0.00 | -- | -- | 0.00 | -149.16 | -- | -173.23 | -- | -- | -- | -- | -- | -- | -370.56 | 0.043 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -34.27m | 17.65m | 25.00 | -- | 1.24 | -- | -- | -0.9553 | -0.9553 | 0.00 | 0.3549 | 0.00 | -- | -- | 0.00 | -103.30 | -- | -150.91 | -- | -- | -- | -- | -- | -- | -260.86 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.45m | 17.85m | 7.00 | -- | 1.78 | -- | -- | -0.7579 | -0.7579 | 0.00 | 0.7188 | 0.00 | -- | -- | 0.00 | -69.61 | -43.88 | -76.92 | -46.26 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.43 | -- | 16.23 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -7.51m | 17.91m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| OpGen Inc | 1.96m | -22.39m | 18.22m | 100.00 | -- | -- | -- | 9.27 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Palatin Technologies, Inc. | 2.38m | -32.35m | 18.35m | 30.00 | -- | -- | -- | 7.70 | -1.98 | -1.98 | 0.1434 | -0.3932 | 0.3252 | -- | -- | 79,470.34 | -441.31 | -55.28 | -- | -69.08 | 95.90 | -- | -1,357.06 | -1,359.14 | -- | -- | -- | -- | -7.49 | -40.52 | -23.71 | -- | 3.31 | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 18.39m | 18.00 | -- | 1.29 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Tenax Therapeutics Inc's reporting currency: US Dollar USD
23.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2024 | 339.55k | 9.96% |
| Adage Capital Management LPas of 30 Sep 2024 | 83.33k | 2.45% |
| Velan Capital Investment Management LPas of 30 Sep 2024 | 83.33k | 2.45% |
| Vestal Point Capital LPas of 30 Sep 2024 | 83.33k | 2.45% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 62.42k | 1.83% |
| Stonepine Capital Management LLCas of 30 Sep 2024 | 50.00k | 1.47% |
| Sphera Funds Management Ltd.as of 30 Sep 2024 | 29.17k | 0.86% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 24.00k | 0.70% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 21.01k | 0.62% |
| Geode Capital Management LLCas of 30 Sep 2024 | 18.39k | 0.54% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
